Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 646191, 9 pages
http://dx.doi.org/10.1155/2012/646191
Research Article

Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial

1Research Group in Animal Pharmacology of Quebec (GREPAQ), Faculty of Veterinary Medicine, Université de Montréal, C.P. 5000, Saint-Hyacinthe, QC, Canada J2S 7C6
2Osteoarthritis Research Unit, Centre Hospitalier de l'Université de Montréal (CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, QC, Canada H2L 4M1
3Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, C.P. 5000, Saint-Hyacinthe, QC, Canada J2S 7C6
4Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Université de Montréal, C.P. 5000, Saint-Hyacinthe, QC, Canada J2S 7C6

Received 7 April 2012; Accepted 30 May 2012

Academic Editor: Vincenzo De Feo

Copyright © 2012 Maxim Moreau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. The aim of this randomized placebo-controlled trial was to evaluate the beneficial effect of a whole plant extract of Brachystemma calycinum D. Don (BCD) in naturally occurring osteoarthritis (OA) in dogs. Methods. Dogs had stifle/hip OA and poor limb loading based on the peak of the vertically oriented ground reaction force (PVF) measured using a force platform. At baseline, PVF and case-specific outcome measure of disability (CSOM) were recorded. Dogs (16 per group) were then assigned to receive BCD (200 mg/kg/day) or a placebo. The PVF was measured at week (W) 3 and W6. Locomotor activity was recorded throughout the study duration using collar-mounted accelerometer, and CSOM was assessed biweekly by the owner. Results. BCD-treated dogs had higher PVF at W3 and W6 when compared to Baseline ( ) and at W6 when compared to placebo-treated dogs ( ). Higher daily duration ( ) and intensity ( ) of locomotor activity were observed in BCD-treated dogs compared to baseline. No significant change was observed in either group for CSOM. Conclusions. Treatment with BCD improved the limb impairment and enhanced the locomotor activity in dogs afflicted by naturally-occurring OA. Those preclinical findings provide interesting and new information about the potential of BCD as an OA therapeutic.